Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganqing granules
- Development stage
- Phase 2
- Lead developer
- Tianjin University of Traditional Chinese Medicine
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Ganqing granules is an investigational Traditional Chinese Medicine (TCM) herbal formulation developed by the Tianjin University of Traditional Chinese Medicine. It is primarily studied for the treatment of non-alcoholic fatty liver disease (NAFLD), specifically for patients diagnosed with the 'phlegm-blood stasis syndrome' (痰瘀阻络证) according to TCM principles. The formulation aims to reduce hepatic fat accumulation and improve liver function, with clinical efficacy measured by liver/spleen CT ratio and ultrasound imaging.
- Other names
- Ganqing Keli
Beyond the preview
Go deeper on Ganqing granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganqing granules.